Loading patent…
AssigneeVestlandets Innovasjonsselskap AS
InventorsØystein Fluge, Olav Mella
Estimating the term…
The present disclosure relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present disclosure relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chronic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.
A method for the treatment of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) comprising administering to a subject in need thereof a therapeutically effective amount of a cytotoxic agent against plasma cells to reduce antibody production, wherein the cytotoxic agent is an antibody directed against CD38 and wherein the antibody directed against CD38 is Daratumumab.
Dependencies are inferred from the claim text.